Does metabolic syndrome increase contrast?induced nephropathy in patients with normal renal function?

Abstract

Background: Contrast?induced nephropathy (CIN) is associated with increased mortality and morbidity in patients undergoing coronary angiography (CAG) and percutaneous coronary intervention. This study aimed to compare the incidence of CIN in two groups of patients with and without metabolic syndrome (Mets) with baseline normal renal function.

Materials and Methods: In this case ? control study, 260 patient candidates for CAG, 130 patients with Mets and 130 patients without Mets participated, and
their serum creatinine (Cr) level before and the 48 and 72 h after the angiography was measured. The incidence of CIN was compared in two groups. Two?way  nalysis of variance with repeated measures and univariate and multivariate logistic regression models.
Results: The results showed a higher chance of being Mets with raising in  riglyceride (adjusted odds ratio = 1.05, 95% confidence interval = (1.03–1.06), P < 0.001), Fasting blood glucose (1.010 [1.001–1.019], P = 0.025), and diastolic blood pressure (1.07 [1.07– 1.20], P < 0.001), but declining in high?density  ipoprotein?cholesterol (HDL?C) (0.91 [0.85–0.98], P = 0.008). Furthermore, blood
urea nitrogen (BUN) and Cr level was raised in 48 and 72 h after contrast injection in both groups (All P < 0.001). Furthermore, in 48 h (3.11 [1.12–9.93], P = 0.016) and 72 h (2.82 [1.07–8.28], P = 0.021) after injection, a total of 25 patients had an increased Cr level and a significant difference between Mets and without Mets groups. The developing Mets had a significant association with the increased risk of AKI, which increased the chance of developing nephropathy (7.14 [2.27–22.5], P = 0.001).

Conclusion: Mets, together with other risk factors, increased the overall risk of CIN development. Therefore, the incidence of CIN in patients Mets is significantly higher than that of patients without Mets, indicating a more important CIN risk factor.